RE: A brilliant month for IMM 350% UP.1 Feb 2025 11:17
THIS PART OF THE STORY CONNECT TO US, ALTHOUGH NOT DIRECTLY..
Another major deal happened recently at the J.P. Morgan Healthcare Conference, where Eli Lilly announced its acquisition of Intra-Cellular Therapies, a company focused on treatments for major depressive disorder. That deal was worth $9 billion, and their lead drug, Lumateperone, is now part of Lilly’s portfolio.
Beyond outright acquisitions, we’re also seeing some creative deal structures. For instance, this week, AbbVie made an option deal for some of the assets of Gilgamesh Pharmaceuticals, a private company working in the psychiatric treatment space. This kind of arrangement allows big pharma to secure rights to promising treatments without committing to a full acquisition upfront.
These recent deals illustrate that major pharmaceutical companies are either acquiring smaller biotechs outright or entering licensing and option agreements. Over the past six months, there’s been a noticeable increase in this kind of activity.
speak soon